Studies with sanguinarine like alkaloids as feed additive in broiler diets

This research included two studies evaluating the live performance of broilers fed Sangrovit® (minimum of 1.5% sanguinarine, a quaternary benzo[c]phenanthridine alkaloid extracted from Macleaya cordata). Both studies were conducted using Ross 308 female broiler chicks. Birds were fed corn-soybean meal all-vegetable diets without growth promoters with 5 treatments and 8 replications in each study. In the first study, treatments were composed of a Negative Control without feed additive and four diets with graded increases of Sangrovit of 12.5, 25, 37.5, and 50 ppm. In the second study, chicks received a similar diet from placement to 21 days of age and subsequently were given feeds with graded reductions in crude protein (CP) as follow: a Negative Control with 19.7% CP without sanguinarine, and then 19.7, 19.2, 18.8 and 18.3% CP supplemented with Sangrovit at 20 ppm. It was demonstrated that body weight was increased when birds were fed 50 ppm of Sangrovit at 21 d when compared to the Negative Control. Also comparatively to the Negative Control, cumulative feed conversion was improved for birds fed with Sangrovit at 37.5 ppm as well as feed intake from placement to 7 days at 12.5 ppm. No differences were observed in feed intake. Birds supplemented with Sangrovit and 18.8% CP had similar body weight gain and feed intake as the Negative Control with 19.7% CP. Mortality in both studies was not correlated with the treatments. Results from both studies indicate benefits of the supplementation of Sangrovit in diets for broilers

Detection of chikungunya virus‐specific IgM on laser‐cut paper‐based device using pseudo‐particles as capture antigen

International audienceThe incidence of arbovirus infections has increased dramatically in recent decades, affecting hundreds of millions of people each year. The Togaviridae family includes the chikungunya virus (CHIKV), which is typically transmitted by Aedes mosquitoes and causes a wide range of symptoms from flu-like fever to severe arthralgia. Although conventional diagnostic tests can provide early diagnosis of CHIKV infections, access to these tests is often limited in developing countries. Consequently, there is an urgent need to develop efficient, affordable, simple, rapid, and robust diagnostic tools that can be used in point-of-care settings. Early diagnosis is crucial to improve patient management and to reduce the risk of complications. A glass-fiber laser-cut microfluidic device (paper-based analytical device [PAD]) was designed and evaluated in a proof of principle context, for the analysis of 30 µL of patient serum. Biological raw materials used for the functionalization of the PAD were first screened by MAC-ELISA (IgM capture enzyme-linked immunosorbent assay) for CHIKV Immunoglobulin M (IgM) capture and then evaluated on the PAD using various human samples. Compared with viral lysate traditionally used for chikungunya (CHIK) serology, CHIKV pseudo-particles (PPs) have proven to be powerful antigens for specific IgM capture. The PAD was able to detect CHIKV IgM in human sera in less than 10 minutes. Results obtained in patient sera showed a sensitivity of 70.6% and a specificity of around 98%. The PAD showed few cross-reactions with other tropical viral diseases. The PAD could help health workers in the early diagnosis of tropical diseases such as CHIK, which require specific management protocols in at-risk populations